Wen Bo Wang | Senior Vice President Of Cell Therapy Research And Development
Cellular Dynamics International Inc.

Wen Bo Wang, Senior Vice President Of Cell Therapy Research And Development, Cellular Dynamics International Inc.

Dr. Wen Bo Wang  Senior Vice President, Cell Therapy R&D, leads internal cell therapy programs at CDI and the next generation production technology development. She directed process development efforts for both iCell products and MyCell products. She managed automation process development for iPSC derivation, cardiomyocyte panel differentiation process optimization, and technology transfer to manufacturing for both NHLBI and CIRM grants. Prior to joining CDI in 2008, Dr. Wang was Group Leader, Process Sciences, at Geron Corporation, Menlo Park, CA. She participated in product development and IND submission for Geron’s dendritic cell based cancer vaccine and embryonic stem cell based cell therapy, and led process development work on cardiomyocyte differentiation. From 2001 to 2005, Dr. Wang held a number of positions at ViaCell, Boston, MA, including Associate Scientific Director, ViaCord Human Umbilical Cord Blood Bank (a sub-division of ViaCell) and process scientist positions in Therapeutic Development. She took part in product development and IND submission for ViaCell's adult stem cell based cell therapy. Dr. Wang earned a B.S. in Biology from Ocean University of Qingdao, P.R. China and received her Ph.D. in Biology from Newcastle University, United Kingdom. She had postdoctoral training in Cryobiology at Biosciences Research Laboratory, USDA/Agricultural Research Service, Fargo, ND, before joining biotech industry in 2001


Advanced Therapies and Regenerative Medicine Day 2 - Thursday 17th May 2018 @ 12:00

Developing cell therapies with iPSC Technologies

  • CDI has four internal cell therapy programs on Ocular, Cardiac, Oncology and Parkinson's disease. Open to strategic partnerships.
  • CDI can offer cGMP iPSC lines from common HLA haplotypes as a platform for cell therapy, with reprogramming license out and contract custom MCB/WCB. Our partners and customers can get a jump start.
  • CDI can provide third parties with contract development and manufacturing services (CDMO) to speed development of their cell therapy project by putting together each party’s unparalleled know-how and expertise

back to speakers



Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257